All In Biotech

Drug Trial Radar · NCT05555706

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

62

Actual

Start

Dec 6, 2022

Primary completion

Sep 30, 2024

Study completion Sep 30, 2024

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Pharmaceuticals Holding Co., Ltd
First posted
Sep 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

Conditions

  • Triple Negative Breast Cancer (TNBC)

Interventions

  • B013+Nab-PaclitaxelDrug

    B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle. Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)(phase Ⅱ)Time frame: Baseline up to approximately 18 months
  2. Progression-free survival (PFS)(IRC) (phase Ⅲ)Time frame: Baseline up to approximately 18 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, China

  • Tianjin medical university cancer institute&hospital

    Tianjin, China

  • Affiliated Cancer Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • Hainan cancer Hospital

    Haikou, Hainan, China

  • The First Affiliated Hospital of henan University of Science and Technoloy

    Luoyang, Henan, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • The Central Hospital of Yongzhou

    Yongzhou, Hunan, China

  • Huai'an First People's Hospital

    Huai'an, Jiangsu, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • The second people's hospital of neijiang

    Neijiang, Sichuan, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.